Heart failure & cardiomyopathies
Colchicine in Acute Heart Failure: Rationale and Design of a Randomized Double-Blind Placebo-Controlled Trial (COLICA)
Study context
- Population
- Acute heart failure (HF) with congestion requiring ≥40 mg IV furosemide and NT-proBNP >900 pg/ml, randomised within 24 h of presentation, irrespective of LVEF, HF type or settingplanned enrolment
- Participants
- 278 participants
- Planned comparison
- Colchicine vs placebo
- Primary endpoint
- Time-averaged proportional change in NT-proBNP concentrations from baseline
- Follow-up
- Week 8
Methodological detailsrationale and design, multicentre, double-blind, placebo-controlled, 12 sites, 1:1 randomisation, Key secondary and exploratory outcomes: symptoms, diuretic use, worsening HF episodes, biomarkers of cardiac stress and inflammation, total and CV readmissions, mortality and safety events
- Rationale and design
- Multicentre
- Double-blind
- Placebo-controlled
- 12 sites
- 1:1 randomisation
- Key secondary and exploratory outcomes: symptoms, diuretic use, worsening HF episodes, biomarkers of cardiac stress and inflammation, total and CV readmissions, mortality and safety events
No results yet. This paper sets out the design of a trial; its results are to come.
Original publication
Colchicine in Acute Heart Failure: Rationale and Design of a Randomized Double-Blind Placebo-Controlled Trial (COLICA). Eur J Heart Fail. Published 4 June 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →